IL270627B2 - Itoxin analogs, their derivatives and their uses - Google Patents

Itoxin analogs, their derivatives and their uses

Info

Publication number
IL270627B2
IL270627B2 IL270627A IL27062719A IL270627B2 IL 270627 B2 IL270627 B2 IL 270627B2 IL 270627 A IL270627 A IL 270627A IL 27062719 A IL27062719 A IL 27062719A IL 270627 B2 IL270627 B2 IL 270627B2
Authority
IL
Israel
Prior art keywords
disorder
compound
etifoxine
disorders
deuterium
Prior art date
Application number
IL270627A
Other languages
English (en)
Hebrew (he)
Other versions
IL270627B (en
IL270627A (enExample
Inventor
Olivier Dasse
Original Assignee
Anvyl Llc
Gaba Therapeutics Llc
Gaba Therapeutics Inc
Olivier Dasse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anvyl Llc, Gaba Therapeutics Llc, Gaba Therapeutics Inc, Olivier Dasse filed Critical Anvyl Llc
Publication of IL270627A publication Critical patent/IL270627A/en
Publication of IL270627B publication Critical patent/IL270627B/en
Publication of IL270627B2 publication Critical patent/IL270627B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL270627A 2015-03-20 2016-03-18 Itoxin analogs, their derivatives and their uses IL270627B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Publications (3)

Publication Number Publication Date
IL270627A IL270627A (enExample) 2019-12-31
IL270627B IL270627B (en) 2022-11-01
IL270627B2 true IL270627B2 (en) 2023-03-01

Family

ID=56977741

Family Applications (2)

Application Number Title Priority Date Filing Date
IL270627A IL270627B2 (en) 2015-03-20 2016-03-18 Itoxin analogs, their derivatives and their uses
IL254567A IL254567B (en) 2015-03-20 2017-09-18 Itoxin analogs, their derivatives and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL254567A IL254567B (en) 2015-03-20 2017-09-18 Itoxin analogs, their derivatives and their uses

Country Status (21)

Country Link
US (4) US10080755B2 (enExample)
EP (1) EP3347006B1 (enExample)
JP (3) JP6762507B2 (enExample)
KR (1) KR102290766B1 (enExample)
CN (1) CN107530323B (enExample)
AU (2) AU2016235495B2 (enExample)
BR (1) BR112017020081B1 (enExample)
CA (1) CA2979853C (enExample)
DK (1) DK3347006T3 (enExample)
ES (1) ES2928396T3 (enExample)
HR (1) HRP20221240T1 (enExample)
HU (1) HUE060240T2 (enExample)
IL (2) IL270627B2 (enExample)
LT (1) LT3347006T (enExample)
MX (1) MX383647B (enExample)
PL (1) PL3347006T3 (enExample)
PT (1) PT3347006T (enExample)
RS (1) RS63654B1 (enExample)
SI (1) SI3347006T1 (enExample)
SM (1) SMT202200407T1 (enExample)
WO (1) WO2016154039A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3347006T3 (pl) * 2015-03-20 2022-11-14 Gaba Therapeutics Inc. Deuterowane analogi etifoksyny, ich pochodne i ich zastosowania
US10420773B2 (en) * 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
CA3093430A1 (en) * 2018-03-23 2019-09-26 Concert Pharmaceuticals, Inc. Deuterated analogs of d-.beta.-hydroxybutyric acid and uses thereof
WO2019222581A1 (en) * 2018-05-18 2019-11-21 Ovid Therapeutics Inc. Methods of treating attention deficit hyperactivity disorder
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2023040851A1 (zh) * 2021-09-14 2023-03-23 南京迈诺威医药科技有限公司 一种水溶性别孕烷醇酮衍生物及其制备方法和用途
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof
WO2024091943A2 (en) * 2022-10-24 2024-05-02 Gaba Therapeutics Inc. Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
WO2025085958A1 (en) * 2023-10-23 2025-05-01 Glomesh Intl Pty Ltd A module for mounting items

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167446A1 (en) * 2005-07-19 2007-07-19 Marc Verleye Neuroprotective compounds and pharmaceutical compositions comprising them

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
CA2646007A1 (en) * 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109288A2 (en) * 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
JP2013535437A (ja) * 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
US20140121407A1 (en) 2011-07-05 2014-05-01 Research Foundation Itsuu Laboratory Deuterated phenylpropionic acid derivative
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
PL3347006T3 (pl) * 2015-03-20 2022-11-14 Gaba Therapeutics Inc. Deuterowane analogi etifoksyny, ich pochodne i ich zastosowania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167446A1 (en) * 2005-07-19 2007-07-19 Marc Verleye Neuroprotective compounds and pharmaceutical compositions comprising them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUTEAU KC:, DEUTERATED DRUGS: UNEXPECTEDLY NONOBVIOUS?, 1 January 2009 (2009-01-01) *
SHAO L ET AL:, DERIVATIVES OF TRAMADOL FOR INCREASED DURATION OF EFFECT, 1 February 2006 (2006-02-01) *

Also Published As

Publication number Publication date
AU2016235495B2 (en) 2020-05-14
ES2928396T3 (es) 2022-11-17
CN107530323B (zh) 2021-05-04
BR112017020081B1 (pt) 2021-11-30
US20180064717A1 (en) 2018-03-08
JP2018508592A (ja) 2018-03-29
SI3347006T1 (sl) 2022-11-30
AU2020201728B2 (en) 2021-12-23
MX383647B (es) 2025-03-14
US10080755B2 (en) 2018-09-25
US20190015419A1 (en) 2019-01-17
CA2979853A1 (en) 2016-09-29
HRP20221240T1 (hr) 2022-12-09
US10736901B2 (en) 2020-08-11
KR20170137085A (ko) 2017-12-12
RS63654B1 (sr) 2022-11-30
US20230263805A1 (en) 2023-08-24
EP3347006A4 (en) 2019-04-24
WO2016154039A1 (en) 2016-09-29
MX2017011978A (es) 2018-02-09
PT3347006T (pt) 2022-10-17
AU2016235495A1 (en) 2017-10-05
US12433896B2 (en) 2025-10-07
EP3347006A1 (en) 2018-07-18
JP6762507B2 (ja) 2020-09-30
JP2021001174A (ja) 2021-01-07
IL254567B (en) 2020-03-31
IL270627B (en) 2022-11-01
IL270627A (enExample) 2019-12-31
US20200405726A1 (en) 2020-12-31
HUE060240T2 (hu) 2023-02-28
CN107530323A (zh) 2018-01-02
DK3347006T3 (da) 2022-10-17
JP7376668B2 (ja) 2023-11-08
PL3347006T3 (pl) 2022-11-14
AU2020201728A1 (en) 2020-03-26
KR102290766B1 (ko) 2021-08-19
JP2023009114A (ja) 2023-01-19
SMT202200407T1 (it) 2022-11-18
LT3347006T (lt) 2022-10-25
CA2979853C (en) 2021-05-11
BR112017020081A2 (pt) 2018-06-05
EP3347006B1 (en) 2022-07-27
IL254567A0 (en) 2017-11-30
US11672805B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
US12433896B2 (en) Deuterated analogs of etifoxine, their derivatives and uses thereof
AU782816B2 (en) Optically active isomers of ketotifen and therapeutically active metabolites thereof
CN1423651A (zh) 新的用途和新的n－氮杂双环－酰胺衍生物
KR20050075013A (ko) 만성 폐쇄 폐질환 치료용 신규 약제
JP2010539218A (ja) Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用
US20080103154A1 (en) 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives
JP2009510041A (ja) Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
JP2019535715A (ja) 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体
US20240189316A1 (en) Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
EP1682523B1 (en) Morpholine derivatives as norepinephrine reuptake inhibitors
EP1355902A1 (en) Sulfonamide compounds, their preparation and use
CN1535273A (zh) 新型2,5-二氮杂二环[2.2.1]庚烷衍生物